Raymond James Financial Services Advisors, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 10,786 shares of ALNY stock, worth $2.51 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,786
Previous 2,197
390.94%
Holding current value
$2.51 Million
Previous $533,000
456.66%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ALNY
# of Institutions
644Shares Held
109MCall Options Held
1.28MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA16.5MShares$3.85 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$2.95 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.23 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.22 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$1.15 Billion0.24% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $28.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...